Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pelthos Therapeutics (PTHS) Treasury Shares (2024 - 2025)

Pelthos Therapeutics has reported Treasury Shares over the past 2 years, most recently at $464921.0 for Q4 2025.

  • Quarterly results put Treasury Shares at $464921.0 for Q4 2025, up 1491.21% from a year ago — trailing twelve months through Dec 2025 was $464921.0 (up 1491.21% YoY), and the annual figure for FY2025 was $464921.0, up 1491.21%.
  • Treasury Shares for Q4 2025 was $464921.0 at Pelthos Therapeutics, up from $29218.0 in the prior quarter.
  • Over the last five years, Treasury Shares for PTHS hit a ceiling of $464921.0 in Q4 2025 and a floor of -$8620.0 in Q3 2024.